Skip to main content

Table 5 Range of bedaquiline prices and CE analysis based on these ranges

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Bedaquiline price threshold analysisa

 

Estonia

Russia

South Africa

Peru

China

Philippines

India

WHO CE thresholds (1x GDP-3x GDP), US$ (Cost per DALY averted)

16,844 – 50,532

14,037 – 42,111

7,352 – 22,056

6,796 – 20,388

6,091 - 18,273

2,587 – 7,761

1,503 – 4,509

Cost-effective price range, US$b

91,984 – 203,492

73,909 – 156,427

29,151 – 72,701

36,421 – 92,953

23,904 – 62,593

8,567 – 22,992

6,996 – 20,323

Bedaquiline plus BR vs. BR alone price range for cost-effectiveness analysis

 Half lowest range price, US$

45,992

36,955

14,576

18,211

11,952

4,284

3,498

 Lowest range price, US$

91,984

73,909

29,151

36,421

23,904

8,567

6,996

 Mid-range price, US$

147,738

115,168

50,926

64,687

43,428

15,285

13,660

 Highest-range price, US$

203,492

156,427

72,701

92,953

62,593

22,002

20,323

 Double highest range price, US$

406,984

312,854

145,402

185,906

125,186

44,004

40,646

  1. BR background regimen, CE cost-effectiveness, DALY disability-adjusted life years, GDP gross domestic product, US United States, WHO World Health Organization
  2. aPrice ranges were chosen in order to satisfy the WHO CE threshold (up to 3x GDP of each country)
  3. bPer 6-month regimen